or
Remember me
Algernon’s business model is based on drug re-purposing, finding new uses for know drugs
Back
News Brief: Algernon Pharmaceuticals $AGN w CEO Christopher Moreau - Initiates Traumatic Brain Injury (TBI) Research Program with AP-188 - https://youtu.be/sN5fFFvCPHc
Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With AP-188; Appoints Global TBI Expert as Advisor
A daily snapshot of everythingfrom market open to close.
info@algernonpharmaceuticals.com investors@algernonpharmaceuticals.com